LIVIVO - Search results -

Search results

Result 1 - 10 of total 104

Search options

Article ; Online: A Novel DNA Variant in

Di Maggio, Federica / Boccia, Giuseppe / Nunziato, Marcella / Filotico, Marcello / Montesarchio, Vincenzo / D'Armiento, Maria / Corcione, Francesco / Salvatore, Francesco

International journal of molecular sciences

2024 Volume 25, Issue 5

Abstract: Colorectal cancer is the third leading cause of death from neoplasia worldwide. Thanks to new screening programs, we are now seeing an increase in Early Onset of ColoRectal Cancer (EOCRC) in patients below the age of 50. Herein, we report a clinical case ...

Abstract	Colorectal cancer is the third leading cause of death from neoplasia worldwide. Thanks to new screening programs, we are now seeing an increase in Early Onset of ColoRectal Cancer (EOCRC) in patients below the age of 50. Herein, we report a clinical case of a woman affected by EOCRC. This case illustrates the importance of genetic predisposition testing also in tumor patients. Indeed, for our patient, we used a combined approach of multiple molecular and cellular biology technologies that revealed the presence of an interesting novel variant in the
MeSH term(s)	Female ; Humans ; Middle Aged ; Colorectal Neoplasms/pathology ; Colonic Neoplasms/genetics ; Genetic Testing ; Genetic Predisposition to Disease ; DNA ; DNA Helicases/genetics ; Nuclear Proteins/genetics ; Transcription Factors/genetics
Chemical Substances	DNA (9007-49-2) ; SMARCA4 protein, human (EC 3.6.1.-) ; DNA Helicases (EC 3.6.4.-) ; Nuclear Proteins ; Transcription Factors
Language	English
Publishing date	2024-02-27
Publishing country	Switzerland
Document type	Case Reports
ZDB-ID	2019364-6
ISSN	1422-0067 ; 1422-0067 ; 1661-6596
ISSN (online)	1422-0067
ISSN	1422-0067 ; 1661-6596
DOI	10.3390/ijms25052716
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Article ; Online: Immunotherapy as a targeted therapy in non-small cell lung cancer.

Rocco, Danilo / Della Gravara, Luigi / Avellino, Aniello / Montesarchio, Vincenzo / Battiloro, Ciro

Translational cancer research

2022 Volume 8, Issue Suppl 1, Page(s) S70–S75

Language	English
Publishing date	2022-01-15
Publishing country	China
Document type	Editorial
ZDB-ID	2901601-0
ISSN	2219-6803 ; 2218-676X
ISSN (online)	2219-6803
ISSN	2218-676X
DOI	10.21037/tcr.2018.10.10
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

Order via subito

Details ▾
- Full text online
- Order with fees

Article: Multimodality Cardiovascular Imaging of Cardiotoxicity Due to Cancer Therapy.

Contaldi, Carla / Montesarchio, Vincenzo / Catapano, Dario / Falco, Luigi / Caputo, Francesca / D'Aniello, Carmine / Masarone, Daniele / Pacileo, Giuseppe

Life (Basel, Switzerland)

2023 Volume 13, Issue 10

Abstract: Cancer therapies have revolutionized patient survival rates, yet they come with the risk of cardiotoxicity, necessitating effective monitoring and management. The existing guidelines offer a limited empirical basis for practical approaches in various ... ...

Abstract	Cancer therapies have revolutionized patient survival rates, yet they come with the risk of cardiotoxicity, necessitating effective monitoring and management. The existing guidelines offer a limited empirical basis for practical approaches in various clinical scenarios. This article explores the intricate relationship between cancer therapy and the cardiovascular system, highlighting the role of advanced multimodality imaging in monitoring patients before, during, and after cancer treatment. This review outlines the cardiovascular effects of different cancer therapy classes, offering a comprehensive understanding of their dose- and time-dependent impacts. This paper delves into diverse imaging modalities such as echocardiography, cardiac magnetic resonance imaging, cardiac computed tomography, and nuclear imaging, detailing their strengths and limitations in various conditions due to cancer treatment, such as cardiac dysfunction, myocarditis, coronary artery disease, Takotsubo cardiomyopathy, pulmonary hypertension, arterial hypertension, valvular heart diseases, and heart failure with preserved ejection fraction. Moreover, it underscores the significance of long-term follow-up for cancer survivors and discusses future directions.
Language	English
Publishing date	2023-10-23
Publishing country	Switzerland
Document type	Journal Article ; Review
ZDB-ID	2662250-6
ISSN	2075-1729
ISSN	2075-1729
DOI	10.3390/life13102103
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: New Insights into the Identification of Metabolites and Cytokines Predictive of Outcome for Patients with Severe SARS-CoV-2 Infection Showed Similarity with Cancer.

Costantini, Susan / Madonna, Gabriele / Di Gennaro, Elena / Capone, Francesca / Bagnara, Palmina / Capone, Mariaelena / Sale, Silvia / Nicastro, Carmine / Atripaldi, Lidia / Fiorentino, Giuseppe / Parrella, Roberto / Montesarchio, Vincenzo / Atripaldi, Luigi / Ascierto, Paolo A / Budillon, Alfredo

International journal of molecular sciences

2023 Volume 24, Issue 5

Abstract: SARS-CoV-2 infection is characterized by several clinical manifestations, ranging from the absence of symptoms to severe forms that necessitate intensive care treatment. It is known that the patients with the highest rate of mortality develop increased ... ...

Abstract	SARS-CoV-2 infection is characterized by several clinical manifestations, ranging from the absence of symptoms to severe forms that necessitate intensive care treatment. It is known that the patients with the highest rate of mortality develop increased levels of proinflammatory cytokines, called the "cytokine storm", which is similar to inflammatory processes that occur in cancer. Additionally, SARS-CoV-2 infection induces modifications in host metabolism leading to metabolic reprogramming, which is closely linked to metabolic changes in cancer. A better understanding of the correlation between perturbed metabolism and inflammatory responses is necessary. We evaluated untargeted plasma metabolomics and cytokine profiling via
MeSH term(s)	Humans ; COVID-19 ; SARS-CoV-2 ; Cytokines ; Neoplasms ; Lactates
Chemical Substances	Cytokines ; Lactates
Language	English
Publishing date	2023-03-03
Publishing country	Switzerland
Document type	Journal Article
ZDB-ID	2019364-6
ISSN	1422-0067 ; 1422-0067 ; 1661-6596
ISSN (online)	1422-0067
ISSN	1422-0067 ; 1661-6596
DOI	10.3390/ijms24054922
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Could asymptomatic carriers spread the SARS-CoV-2 infection? Experience from the Italian second wave.

Atripaldi, Luigi / Sale, Silvia / Capone, Mariaelena / Montesarchio, Vincenzo / Parrella, Roberto / Botti, Gerardo / Ascierto, Paolo Antonio / Madonna, Gabriele

Journal of translational medicine

2021 Volume 19, Issue 1, Page(s) 93

MeSH term(s)	COVID-19 ; China ; Communicable Disease Control ; Humans ; Italy/epidemiology ; Nucleic Acids ; SARS-CoV-2
Chemical Substances	Nucleic Acids
Language	English
Publishing date	2021-03-02
Publishing country	England
Document type	Letter ; Research Support, Non-U.S. Gov't ; Comment
ISSN	1479-5876
ISSN (online)	1479-5876
DOI	10.1186/s12967-021-02762-0
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: First-line cetuximab + platinum-based therapy for recurrent/metastatic head and neck squamous cell carcinoma: A real-world observational study-ENCORE.

Le Tourneau, Christophe / Ghiani, Massimo / Cau, Maria Chiara / Depenni, Roberta / Ronzino, Graziana / Bonomo, Pierluigi / Montesarchio, Vincenzo / Leo, Luigi / Schulten, Jeltje / Salmio, Satu / Messinger, Diethelm / Sbrana, Andrea / Borcoman, Edith / Ghi, Maria Grazia

Cancer reports (Hoboken, N.J.)

2023 Volume 6, Issue 5, Page(s) e1804

Abstract: Background: ENCORE, an observational, prospective, open-label study, investigated real-world treatment practices and outcomes with cetuximab plus platinum-based therapy (PBT) in first-line (1L) recurrent and/or metastatic squamous cell carcinoma of the ... ...

Abstract	Background: ENCORE, an observational, prospective, open-label study, investigated real-world treatment practices and outcomes with cetuximab plus platinum-based therapy (PBT) in first-line (1L) recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN). Aims: This multinational study aimed to investigate the long-term use of cetuximab plus PBT for 1L R/M SCCHN in a clinical setting. In particular, this study aimed to explore clinical considerations such as the decision to prescribe cetuximab plus PBT in R/M SCCHN, the mode and duration of treatment, and patient outcomes. Methods and results: Previously untreated patients with R/M SCCHN whose planned treatment was cetuximab plus PBT were enrolled from 6 countries. Among 221 evaluable patients, planned treatments included cetuximab plus carboplatin (31.2%), cisplatin plus 5-fluorouracil (31.7%), or carboplatin plus 5-fluorouracil (23.1%); 3.2% included a taxane, and 45.2% did not include 5-fluorouracil. Cetuximab treatment was planned for a fixed duration (≤24 weeks) in 15 patients (6.8%) and until disease progression in 206 (93.2%). Median progression-free survival and overall survival were 6.5 and 10.8 months, respectively. Grade ≥3 adverse events occurred in 39.8% of patients. Serious adverse events occurred in 25.8% of patients; 5.4% were cetuximab-related. Conclusion: In patients with R/M SCCHN, first-line cetuximab plus PBT was feasible and modifiable in a real-world setting with similar toxicity and efficacy as in the pivotal phase III EXTREME trial. Clinical trial registration number: EMR 062202-566.
MeSH term(s)	Humans ; Cetuximab/adverse effects ; Squamous Cell Carcinoma of Head and Neck/drug therapy ; Platinum/therapeutic use ; Carboplatin ; Prospective Studies ; Neoplasm Recurrence, Local/pathology ; Head and Neck Neoplasms/drug therapy ; Fluorouracil ; Cisplatin
Chemical Substances	Cetuximab (PQX0D8J21J) ; Platinum (49DFR088MY) ; Carboplatin (BG3F62OND5) ; Fluorouracil (U3P01618RT) ; Cisplatin (Q20Q21Q62J)
Language	English
Publishing date	2023-04-17
Publishing country	United States
Document type	Observational Study ; Journal Article ; Research Support, Non-U.S. Gov't
ISSN	2573-8348
ISSN (online)	2573-8348
DOI	10.1002/cnr2.1804
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Panitumumab plus trifluridine/tipiracil as anti-EGFR rechallenge therapy in patients with refractory RAS wild-type metastatic colorectal cancer: Overall survival and subgroup analysis of the randomized phase II VELO trial.

Napolitano, Stefania / Ciardiello, Davide / De Falco, Vincenzo / Martini, Giulia / Martinelli, Erika / Della Corte, Carminia Maria / Esposito, Lucia / Famiglietti, Vincenzo / Di Liello, Alessandra / Avallone, Antonio / Cardone, Claudia / De Stefano, Alfonso / Montesarchio, Vincenzo / Zampino, Maria Giulia / Fazio, Nicola / Di Maio, Massimo / Del Tufo, Sara / De Vita, Ferdinando / Altucci, Lucia /

Marrone, Francesca / Ciardiello, Fortunato / Troiani, Teresa

International journal of cancer

2023 Volume 153, Issue 8, Page(s) 1520–1528

Abstract: The randomized phase II VELO trial showed that the addition of panitumumab to trifluridine/tipiracil significantly improves progression-free survival (PFS) as compared to trifluridine/tipiracil in third-line therapy in patients with refractory RAS wild- ... ...

Abstract	The randomized phase II VELO trial showed that the addition of panitumumab to trifluridine/tipiracil significantly improves progression-free survival (PFS) as compared to trifluridine/tipiracil in third-line therapy in patients with refractory RAS wild-type (WT) metastatic colorectal cancer (mCRC). With longer follow-up, final overall survival results and posttreatment subgroup analysis are presented. Sixty-two patients with refractory RAS WT mCRC were randomly assigned to receive, as third-line therapy, trifluridine/tipiracil alone (arm A) or in combination with panitumumab (arm B). Primary endpoint was PFS; secondary endpoints included overall survival (OS) and overall response rate (ORR). Median OS was 13.1 months (95% CI 9.5-16.7) in arm A compared to 11.6 months (95% CI 6.3-17.0) in arm B (HR: 0.96, 95% CI 0.54-1.71, P = .9). To evaluate the impact of subsequent lines of treatment, subgroup analysis was performed for the 24/30 patients in arm A, that received fourth-line therapy after disease progression. Median PFS was 4.1 months (95% CI 1.44-6.83) for 17 patients treated with anti-EGFR rechallenge as compared to 3.0 months (95% CI 1.61-4.31) for seven patients that received other therapies (HR: 0.29, 95% CI 0.10-0.85, P = .024). Median OS from the start of fourth-line treatment was 13.6 months (95% CI 7.2-20), and 5.1 months (95% CI 1.8-8.3) for patients treated with anti-EGFR rechallenge vs other therapies, respectively (HR: 0.30, 95% CI 0.11-0.81, P = .019). Final results of the VELO trial support the role of anti-EGFR rechallenge in the continuum of care of patients with RAS/BRAF WT mCRC.
MeSH term(s)	Humans ; Panitumumab/therapeutic use ; Colorectal Neoplasms/drug therapy ; Colorectal Neoplasms/genetics ; Trifluridine/therapeutic use ; Colonic Neoplasms/etiology ; Rectal Neoplasms/etiology ; Antineoplastic Combined Chemotherapy Protocols
Chemical Substances	Panitumumab (6A901E312A) ; tipiracil (NGO10K751P) ; Trifluridine (RMW9V5RW38)
Language	English
Publishing date	2023-06-30
Publishing country	United States
Document type	Randomized Controlled Trial ; Clinical Trial, Phase II ; Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	218257-9
ISSN	1097-0215 ; 0020-7136
ISSN (online)	1097-0215
ISSN	0020-7136
DOI	10.1002/ijc.34632
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 478: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 576: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Panitumumab Plus Trifluridine-Tipiracil as Anti-Epidermal Growth Factor Receptor Rechallenge Therapy for Refractory RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Randomized Clinical Trial.

Napolitano, Stefania / De Falco, Vincenzo / Martini, Giulia / Ciardiello, Davide / Martinelli, Erika / Della Corte, Carminia Maria / Esposito, Lucia / Famiglietti, Vincenzo / Di Liello, Alessandra / Avallone, Antonio / Cardone, Claudia / De Stefano, Alfonso / Montesarchio, Vincenzo / Zampino, Maria Giulia / Bordonaro, Roberto / Scartozzi, Mario / Santini, Daniele / Di Maio, Massimo / De Vita, Ferdinando /

Altucci, Lucia / Marrone, Francesca / Ciardiello, Fortunato / Troiani, Teresa

JAMA oncology

2023 Volume 9, Issue 7, Page(s) 966–970

Abstract: Importance: Current third-line therapies for patients with metastatic colorectal cancer (MCRC) have limited efficacy. Rechallenge with epidermal growth factor receptor (EGFR) inhibitors for RAS wild-type (WT) MCRC may be valuable for these patients.: ... ...

Abstract	Importance: Current third-line therapies for patients with metastatic colorectal cancer (MCRC) have limited efficacy. Rechallenge with epidermal growth factor receptor (EGFR) inhibitors for RAS wild-type (WT) MCRC may be valuable for these patients. Objective: To compare the anti-EGFR monoclonal antibody panitumumab plus standard-of-care trifluridine-tipiracil with trifluridine-tipiracil alone as third-line therapy for RAS WT MCRC. Design, setting, and participants: This phase 2 randomized clinical trial (RCT) was conducted in 7 Italian centers from June 2019 to April 2022. Patients with refractory RAS WT MCRC who had a partial or complete response to first-line chemotherapy plus an anti-EGFR monoclonal antibody and an anti-EGFR drug-free interval of 4 or more months during second-line therapy were included. Interventions: Patients were randomized 1:1 to receive panitumumab plus trifluridine-tipiracil or trifluridine-tipiracil alone. Main outcomes and measures: The primary end point was progression-free survival (PFS). Circulating tumor DNA (ctDNA) extended sequence variation analysis was performed in a subgroup of patients. Results: Of 62 included patients, 31 received panitumumab plus trifluridine-tipiracil (19 [61.3%] male; median age, 65 years [range, 39-81 years]) and 31 received trifluridine-tipiracil alone (17 [54.8%] male; median age, 66 years [range, 32-82 years]). The primary end point was met. Median PFS was 4.0 months (95% CI, 2.8-5.3 months) in the panitumumab plus trifluridine-tipiracil arm vs 2.5 months (95% CI, 1.4-3.6 months) in the trifluridine-tipiracil only (hazard ratio [HR], 0.48; 95% CI, 0.28-0.82; P = .007). Pretreatment plasma RAS/BRAF WT ctDNA identified patients obtaining prolonged clinical benefit with panitumumab plus trifluridine-tipiracil compared with trifluridine-tipiracil, with PFS rates at 6 months of 38.5% vs 13.0% and at 12 months of 15.4% vs 0%. A ctDNA liquid-biopsy extended mutation analysis by FoundationOne Liquid CDx (profiling 324 genes) was performed in a subgroup of patients with baseline plasma RAS/BRAF WT ctDNA; in 15 of 23 patients (65.2%) whose tumors were WT for KRAS, NRAS, BRAFV600E, EGFR, ERBB2, MAP2K1, and PIK3CA, median PFS was 6.4 months (95% CI, 3.7-9.2 months). Within this group of 15 patients, 2 (13.3%) had partial response, 11 (73.3%) had stable disease, and 2 (13.3%) had disease progression as best response. Conclusions and relevance: In this RCT, third-line treatment with the anti-EGFR monoclonal antibody panitumumab plus the standard-of-care trifluridine-tipiracil resulted in improved PFS compared with treatment with trifluridine-tipiracil alone among patients with refractory RAS WT MCRC. The findings support the clinical utility of liquid biopsy-guided anti-EGFR rechallenge therapy for refractory RAS WT MCRC. Trial registration: ClinicalTrials.gov Identifier: NCT05468892.
MeSH term(s)	Aged ; Female ; Humans ; Male ; Antibodies, Monoclonal/therapeutic use ; Antineoplastic Agents/therapeutic use ; Antineoplastic Combined Chemotherapy Protocols ; Colorectal Neoplasms/drug therapy ; Colorectal Neoplasms/genetics ; Colorectal Neoplasms/pathology ; Panitumumab/therapeutic use ; Proto-Oncogene Proteins B-raf/genetics ; Trifluridine/therapeutic use
Chemical Substances	Antibodies, Monoclonal ; Antineoplastic Agents ; Panitumumab (6A901E312A) ; Proto-Oncogene Proteins B-raf (EC 2.7.11.1) ; tipiracil (NGO10K751P) ; Trifluridine (RMW9V5RW38)
Language	English
Publishing date	2023-08-22
Publishing country	United States
Document type	Clinical Trial, Phase II ; Journal Article ; Randomized Controlled Trial ; Research Support, Non-U.S. Gov't
ISSN	2374-2445
ISSN (online)	2374-2445
DOI	10.1001/jamaoncol.2023.0655
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Chemotherapy and/or immune checkpoint inhibitors in NSCLC first-line setting: what is the best approach?

Gravara, Luigi Della / Battiloro, Ciro / Cantile, Rosa / Letizia, Antonietta / Vitiello, Fabiana / Montesarchio, Vincenzo / Rocco, Danilo

Lung cancer management

2020 Volume 9, Issue 1, Page(s) LMT22

Language	English
Publishing date	2020-02-12
Publishing country	England
Document type	Editorial
ZDB-ID	2669715-4
ISSN	1758-1974 ; 1758-1966
ISSN (online)	1758-1974
ISSN	1758-1966
DOI	10.2217/lmt-2019-0018
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

Order via subito

Details ▾
- Full text online
- Order with fees

Article ; Online: Could asymptomatic carriers spread the SARS-CoV-2 infection? Experience from the Italian second wave

Luigi Atripaldi / Silvia Sale / Mariaelena Capone / Vincenzo Montesarchio / Roberto Parrella / Gerardo Botti / Paolo Antonio Ascierto / Gabriele Madonna

Journal of Translational Medicine, Vol 19, Iss 1, Pp 1-

2021 Volume 4

Keywords	Medicine ; R
Language	English
Publishing date	2021-03-01T00:00:00Z
Publisher	BMC
Document type	Article ; Online
Database	BASE - Bielefeld Academic Search Engine (life sciences selection)

Full text online

Full text

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

To top

More links

Kategorien

Order via subito

Full text online

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

Full text online

More links

Kategorien

Order via subito

Full text online

More links

Kategorien

Inter-library loan at ZB MED